Johnson & Johnson has set up a pre-competitive initiative designed to increase efficiencies in clinical trials and peers Merck & Co and Eli Lilly have decided to participate in the scheme.
J&J’s Janssen R&D unit has unveiled what it calls “a global cross-pharmaceutical investigator databank”, which will serve as “a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed”. This will allow participating companies to “reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites”.
The databank will house critical information about investigators and trial sites in one place, “making it easier for companies to identify appropriate trial sites and investigators for future clinical trials”. Andreas Koester, head of clinical trial innovation/external alliances at Janssen R&D, said the current environment “is inefficient, costly and unsustainable”, adding that the investigator databank can help “expedite the process…to deliver high-quality, effective novel medicines to the patients who are waiting for them”. Read more